Original Article

You have full text access to this OnlineOpen article

Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients

  1. Alessandra Testa1,
  2. Francesca Mallamaci1,
  3. Francesco A Benedetto2,
  4. Anna Pisano1,
  5. Giovanni Tripepi1,
  6. Lorenzo Malatino4,
  7. Ravi Thadhani3,
  8. Carmine Zoccali1,*

Article first published online: 18 DEC 2009

DOI: 10.1359/jbmr.090717

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 2, pages 313–319, February 2010

Additional Information

How to Cite

Testa, A., Mallamaci, F., Benedetto, F. A., Pisano, A., Tripepi, G., Malatino, L., Thadhani, R. and Zoccali, C. (2010), Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. Journal of Bone and Mineral Research, 25: 313–319. doi: 10.1359/jbmr.090717

Author Information

  1. 1

    CNR-IBIM, Research Unit of Clinical Epidemiology and Physiopathology of Renal Disease and Hypertension, Reggio Calabria, Italy

  2. 2

    Cardiology Unit, Morelli Hospital, Reggio Calabria, Italy

  3. 3

    Division of Internal Medicine, University of Catania, c/o Ospedale Cannizzaro, Catanua, Italy

  4. 4

    Renal Unit and the Center for D-Receptor Activation Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

*Professor Carmine Zoccali CNR-IBIM, CNR e Nefrologia, Ospedali Riuniti, c/o EUROLINE di Ascrizzi Vincenzo, Via Vallone Petrara 55-57, 89124 Reggio Calabria, Italy.

Publication History

  1. Issue published online: 19 FEB 2010
  2. Article first published online: 18 DEC 2009
  3. Manuscript Accepted: 6 JUL 2009
  4. Manuscript Revised: 4 FEB 2009
  5. Manuscript Received: 27 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (108K)

References

  • 1
    Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996; 11: 1277–1285.
  • 2
    Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 200112: 2768–2774.
  • 3
    Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001; 12: 1079–1084.
  • 4
    Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41–46.
  • 5
    Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002; 62: 339–345.
  • 6
    Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 1004–1013.
  • 7
    Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125–E132.
  • 8
    Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol. 2007; 103: 533–537.
  • 9
    Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 Vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577–1588.
  • 10
    Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007; 104: 16810–16815.
  • 11
    McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron. 1984; 36: 94–100.
  • 12
    Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis, 1999; 33: 73–81.
  • 13
    Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006; 102: c21–c29.
  • 14
    Davey SG, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003; 32: 1–22.
  • 15
    Marco MP, Craver L, Betriu A, Fibla J, Fernandez E. Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38: 965–974.
  • 16
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
  • 17
    Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–2117.
  • 18
    De Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 1251–1260.
  • 19
    Zoccali C, Mallamaci F, Tripepi G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 1751–1758.
  • 20
    Lunetta KL. Genetic association studies. Circulation 2008; 118: 96–101.
  • 21
    Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J. 2004; 5: 505–510.
  • 22
    Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65: 1492–1498.
  • 23
    London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12: 2759–2767.
  • 24
    Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007; 298: 1291–1299.
  • 25
    Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004; 19: 419–428.
  • 26
    Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. 2006; 371: 1–12.
  • 27
    Erturk S, Kutlay S, Karabulut HG, et al. The impact of vitamin D receptor genotype on the management of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40: 816–823.
  • 28
    Krause R, Roth HJ, Edenharter G, et al. Vitamin D deficiency and cardiac mortality in patients on renal replacement therapy (RRT). American Society of Nephrology Congress, 2008, abstract F-FC322 JASN 19, abstract issue 73A.
  • 29
    London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613–620.
View Full Article (HTML) Get PDF (108K)